Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVID-19 Vaccine GC4006A in Healthy Adults
NCT07728396Phase 1Active, not recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Jan 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GC4006A in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by GC Biopharma Corp. Primary endpoints: Solicited local and systemic adverse events at 7 days, Acute adverse events at 30 minutes and 1 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
GC4006A
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07728396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728396.